Clinical Research Directory

Inclusion Criteria: * Aged ≥18 years, male or female, with no gender restriction. * Planned for EUS-GE for malignant gastric outlet obstruction (GOO). * Technically successful EUS-GE: correct stent position is intra-operatively confirmed comprehensively via fluoroscopy-aided contrast injection through the stent and dye solution flowing into the stomach through the stent; no severe adverse events requiring urgent surgical or interventional management occur during the procedure. * Planned LAMS indwelling for at least 6 months, and willingness to undergo scheduled gastroscopy evaluations at 3-month and 6-month post-procedure. * Able to take oral study medications per protocol after significant relief of obstructive symptoms. * The subject or legal representative is fully informed and provides written informed consent Exclusion Criteria: * Definite indication for long-term proton-pump inhibitor (PPI) therapy that cannot be discontinued or de-escalated, including active peptic ulcer disease, recent upper gastrointestinal bleeding, Los Angeles grade C/D reflux esophagitis, Zollinger-Ellison syndrome, antithrombotic or NSAID therapy judged by the investigator to require continuous gastric mucosal protection, etc. * Active gastric or duodenal ulcer, overt gastrointestinal bleeding within 7 days prior to enrollment, or unexplained persistent hemoglobin decline. * Ongoing treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or high-dose glucocorticoids; or inability to adjust anticoagulant and antiplatelet agents per study protocol. * INR \> 1.5, platelet count \< 50 × 10⁹/L, or other uncorrected severe coagulopathy. * Severe cardiac, pulmonary, hepatic or renal insufficiency; pregnancy or lactation. * Hypersensitivity to esomeprazole, other benzimidazole-class agents, or excipients. * Concurrent participation in other interventional clinical trials that may affect the primary endpoint. * Poor compliance judged by the investigator; inability to complete electronic medication records or scheduled gastroscopic follow-up.